Consolidative allogeneic HCT vs. a watch-and-wait approach for B-cell acute lymphoblastic leukemia patients with early loss of B-cell aplasia after CAR T-cell therapy.


Por: Camarillas S, Alonso-Saladrigues A, Navarro V, Marsal-Ricoma J, Molinos Á, Delgado J, Herrero B, Rampotas A, Roddie C, Bücklein V, Subklewe M, Sánchez-Salinas M, González-Martínez B, Martin AÁ, Torrent A, Pérez-Martínez A, Iacoboni G, Rives-Solà S and Barba P

Ahead of Print: 29 sep 2026
Resumen:


Filiaciones:
Camarillas S:
 Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain

 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

Alonso-Saladrigues A:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Hospital Sant Joan de Déu Department of Pediatric Hematology and Oncology, Barcelona, Spain

Navarro V:
 Oncology Data Science Group, Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Marsal-Ricoma J:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Hospital Sant Joan de Déu Department of Pediatric Hematology and Oncology, Barcelona, Spain

Molinos Á:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 University Hospital Virgen del Rocío, Sevilla, Spain

Delgado J:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 University Hospital Virgen del Rocío, Sevilla, Spain

Herrero B:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Niño Jesús University Children's Hospital, Madrid, Spain

Rampotas A:
 University College of London Cancer Institute, London, UK

Roddie C:
 University College of London Cancer Institute, London, UK

Bücklein V:
 LMU University Hospital, München, Germany

Subklewe M:
 LMU University Hospital, München, Germany

Sánchez-Salinas M:
 Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain

 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Cellular Engineering and Hematologic Immunotherapy lab. Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain

González-Martínez B:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Department of Pediatric Hemato-Oncology, University Hospital La Paz, Madrid, Spain

Martin AÁ:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Hospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), Salamanca, Spain

Torrent A:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona, Spain

Pérez-Martínez A:
 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Department of Pediatric Hemato-Oncology, University Hospital La Paz, Madrid, Spain

 IdiPAZ-CNIO Pediatric Onco-Hematology Clinical Research Unit, University Hospital La Paz, Madrid, Spain

Iacoboni G:
 Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain

 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Cellular Engineering and Hematologic Immunotherapy lab. Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Rives-Solà S:
 Hospital Sant Joan de Déu Department of Pediatric Hematology and Oncology, Barcelona, Spain

 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

Barba P:
 Department of Hematology, Vall d'Hebron University Hospital, Barcelona, Spain

 Spanish Transplant and Cell Therapy Group (GETH-TC), Madrid, Spain

 Cellular Engineering and Hematologic Immunotherapy lab. Vall D'Hebron Institute of Oncology (VHIO), Barcelona, Spain
ISSN: 02683369





BONE MARROW TRANSPLANTATION
Editorial
SPRINGERNATURE, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Letter
Volumen: Número:
Páginas:
WOS Id: 001889039000001
ID de PubMed: 42811067

MÉTRICAS